Homocisteína y deterioro cognitivo en la enfermedad de Parkinson

Martín-Fernández, José Javier; Carles-Díes, Rafael; Cañizares, Francisco Seva; Parra, Soledad; Avilés, Francisco; Villegas, Irene Fernández; Morsi-Hassan, Ossama; Fernández-Barreiro, A; Herrero, María Trinidad

doi:10.33588/rn.5003.2009276

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, the study of Martin et al 2010 showed higher Hcy levels in PD patients with levodopa treatment and cognitive impairment compared with those levodopa treated patients without cognitive impairment (13).…”

Section: Parkinson´s Diseasementioning

confidence: 91%

“…There is growing evidence that higher Hcy levels are involved in age-related cognitive deficits and various types of central nervous system (CNS) disorders (11), including Alzheimer´s disease (AD) (12), Parkinson disease (PD) (13), multiple sclerosis (MS) (14), cerebrovascular diseases and strokes (15). The relationship between HHcy and age-related neurodegeneration has also been highlighted (16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Homocysteine and cognition: A systematic review of 111 studies

Setién-Suero

Suárez-Pinilla

et al. 2016

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

show abstract

Section: Parkinson´s Diseasementioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Homocysteine and cognition: A systematic review of 111 studies

Setién-Suero

Suárez-Pinilla

et al. 2016

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

show abstract

“…However, the literature on Hcy levels and cognitive impairment in PD is mixed. Some reports have found impaired cognition in PD patients with hyperhomocysteinemia [7,[11][12][13][14][15][16][17][18], while others found no relationship between Hcy levels and cognitive impairment in PD [19,20]. The discrepancies in the literature can be attributed to the sample size, the comprehensiveness of cognitive tests, or the interindividual genetic variability.…”

Section: Introductionmentioning

confidence: 99%

Homocysteine levels, genetic background, and cognitive impairment in Parkinson’s disease

et al. 2022

View full text Add to dashboard Cite

Background Hyperhomocysteinemia is considered an independent risk factor for cognitive impairment. Objective To study the correlation between homocysteine levels and cognitive impairment in patients with PD. Methods We conducted a case–control study that included 246 patients with PD, of whom 32 were cognitively impaired. The levels of homocysteine, folate, and vitamin B12 were measured in peripheral blood. Multivariate logistic regression analysis was applied to determine differences in homocysteine levels between PD patients with and without cognitive impairment. A meta-analysis was performed to clarify the role of Hcy levels in PD with cognitive decline. Five polymorphisms in genes involved in Hcy metabolism, including MTHFR rs1801133 and rs1801131, COMT rs4680, MTRR rs1801394, and TCN2 rs1801198, were genotyped. Results Our case–control study showed that homocysteine levels were associated with cognitive impairment in PD after adjusting for possible confounding factors such as levodopa equivalent daily dose. The results of our meta-analysis further supported the positive association between homocysteine levels and cognition in PD. We found that the MTHFR rs1801133 TT genotype led to higher homocysteine levels in PD patients, whereas the MTHFR rs1801131 CC genotype resulted in higher folate levels. However, the polymorphisms studied were not associated with cognitive impairment in PD. Conclusions Increased homocysteine levels were a risk factor for cognitive decline in PD. However, no association was found between polymorphisms in genes involved in homocysteine metabolism and cognitive impairment in PD. Large-scale studies of ethnically diverse populations are required to definitively assess the relationship between MTHFR and cognitive impairment in PD.

show abstract